-
2
-
-
0031800635
-
The mammalian carboxylesterases: From molecules to function
-
Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to function. Annu Rev Pharmacol Toxicol 1998;38:257-88.
-
(1998)
Annu Rev Pharmacol Toxicol
, vol.38
, pp. 257-288
-
-
Satoh, T.1
Hosokawa, M.2
-
4
-
-
0032929154
-
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
-
Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999;5:917-24.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 917-924
-
-
Danks, M.K.1
Morton, C.L.2
Krull, E.J.3
-
5
-
-
0034282809
-
Proficient metabolism of CPT-11 by a human intestinal carboxylesterase
-
Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of CPT-11 by a human intestinal carboxylesterase. Cancer Res 2000;60: 4725-8.
-
(2000)
Cancer Res
, vol.60
, pp. 4725-4728
-
-
Khanna, R.1
Morton, C.L.2
Danks, M.K.3
Potter, P.M.4
-
6
-
-
0033870254
-
Activation of CPT-11 in mice: Identification and analysis of a highly effective plasma esterase
-
Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000;60:4206-10.
-
(2000)
Cancer Res
, vol.60
, pp. 4206-4210
-
-
Morton, C.L.1
Wierdl, M.2
Oliver, L.3
-
7
-
-
0032526239
-
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11)
-
Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998;52: 2646-51.
-
(1998)
Cancer Res
, vol.52
, pp. 2646-2651
-
-
Potter, P.M.1
Pawlik, C.A.2
Morton, C.L.3
Naeve, C.W.4
Danks, M.K.5
-
8
-
-
0028364014
-
Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
-
Satoh T, Hosokawa M, Atsumi R, et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994;17:662-4.
-
(1994)
Biol Pharm Bull
, vol.17
, pp. 662-664
-
-
Satoh, T.1
Hosokawa, M.2
Atsumi, R.3
-
9
-
-
0035392963
-
Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase
-
Wierdl M, Morton CL, Weeks JK, et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001;61:5078-82.
-
(2001)
Cancer Res
, vol.61
, pp. 5078-5082
-
-
Wierdl, M.1
Morton, C.L.2
Weeks, J.K.3
-
10
-
-
0027324850
-
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
-
Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993;53:2823-39.
-
(1993)
Cancer Res
, vol.53
, pp. 2823-2839
-
-
Houghton, P.J.1
Cheshire, P.J.2
Hallman, J.C.3
-
11
-
-
0029116438
-
Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
-
Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan, and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
-
(1995)
Cancer Chemother Pharmacol
, vol.36
, pp. 393-403
-
-
Houghton, P.J.1
Cheshire, P.J.2
Hallman II, J.D.3
-
12
-
-
0029165929
-
Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan
-
Bonneterre J. Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan. Bull Cancer 1995;82:623-8.
-
(1995)
Bull Cancer
, vol.82
, pp. 623-628
-
-
Bonneterre, J.1
-
13
-
-
0000148072
-
Efficacy of irinotecan HCI (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy
-
Bugat R, Rougier P, Douillard JY, et al. Efficacy of irinotecan HCI (CPT11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU-based chemotherapy. Proc Am Soc Clin Oncol Annu Meet 1995;14:A567.
-
(1995)
Proc Am Soc Clin Oncol Annu Meet
, vol.14
-
-
Bugat, R.1
Rougier, P.2
Douillard, J.Y.3
-
14
-
-
0029919598
-
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
-
Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-15.
-
(1996)
J Clin Oncol
, vol.14
, pp. 709-715
-
-
Conti, J.A.1
Kemeny, N.E.2
Saltz, L.B.3
-
15
-
-
0029964872
-
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation
-
Cunningham D. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer 1996;32A Suppl 3:S1-8.
-
(1996)
Eur J Cancer
, vol.32 A
, Issue.SUPPL. 3
-
-
Cunningham, D.1
-
17
-
-
0842308823
-
Progress in treatment of small-cell lung cancer: Role of CPT-11
-
Saijo N. Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer 2003;89:2178-83.
-
(2003)
Br J Cancer
, vol.89
, pp. 2178-2183
-
-
Saijo, N.1
-
18
-
-
0033039308
-
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
-
Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1815-1824
-
-
Furman, W.L.1
Stewart, C.F.2
Poquette, C.A.3
-
19
-
-
0029857839
-
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
-
Armand JP, Extra YM, Catimel G, et al. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol 1996;7:837-42.
-
(1996)
Ann Oncol
, vol.7
, pp. 837-842
-
-
Armand, J.P.1
Extra, Y.M.2
Catimel, G.3
-
20
-
-
0000291599
-
A phase I trial to evaluate orally administered irinotecan HCL (CPT-11) given daily x 5 every 3 weeks in patients with refractory malignancies
-
Drengler R, Burris H, Dietz A, et al. A phase I trial to evaluate orally administered irinotecan HCL (CPT-11) given daily x 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol Annu Meet 1996;15:A1560.
-
(1996)
Proc Am Soc Clin Oncol Annu Meet
, vol.15
-
-
Drengler, R.1
Burris, H.2
Dietz, A.3
-
21
-
-
0011805038
-
Phase I trial of irinotecan (CPT-11), 5-fluorouracil (FU), and leucovorin (LV) in patients with advanced solid tumors
-
Saltz L, Kanowitz J, Kemeny N, et al. Phase I trial of irinotecan (CPT-11), 5-fluorouracil (FU), and leucovorin (LV) in patients with advanced solid tumors. Proc Am Soc Clin Oncol Annu Meet 1995;14:A1546.
-
(1995)
Proc Am Soc Clin Oncol Annu Meet
, vol.14
-
-
Saltz, L.1
Kanowitz, J.2
Kemeny, N.3
-
23
-
-
33749553841
-
VDEPT using a rabbit liver carboxylesterase and CPT-11
-
Morton CL, Wierdl M, Houghton PJ, Danks MK, Potter PM. VDEPT using a rabbit liver carboxylesterase and CPT-11. Proc Am Assoc Cancer Res 2004;45:871.
-
(2004)
Proc Am Assoc Cancer Res
, vol.45
, pp. 871
-
-
Morton, C.L.1
Wierdl, M.2
Houghton, P.J.3
Danks, M.K.4
Potter, P.M.5
-
24
-
-
26444585076
-
Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice
-
Morton CL, Iacono L, Hyatt JL, et al. Metabolism and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56:629-36.
-
(2005)
Cancer Chemother Pharmacol
, vol.56
, pp. 629-636
-
-
Morton, C.L.1
Iacono, L.2
Hyatt, J.L.3
-
25
-
-
2442679029
-
Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity
-
Wadkins RM, Hyatt JL, Yoon KJ, et al. Identification of novel selective human intestinal carboxylesterase inhibitors for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004;65: 1336-43.
-
(2004)
Mol Pharmacol
, vol.65
, pp. 1336-1343
-
-
Wadkins, R.M.1
Hyatt, J.L.2
Yoon, K.J.3
-
26
-
-
20944443990
-
Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases
-
Wadkins RM, Hyatt JL, Wei X, et al. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 2005;48:2905-15.
-
(2005)
J Med Chem
, vol.48
, pp. 2905-2915
-
-
Wadkins, R.M.1
Hyatt, J.L.2
Wei, X.3
-
27
-
-
0016365032
-
Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods
-
Beaufay H, Amar-Costesec A, Feytmans E, et al. Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol 1974;61:188-200.
-
(1974)
J Cell Biol
, vol.61
, pp. 188-200
-
-
Beaufay, H.1
Amar-Costesec, A.2
Feytmans, E.3
-
28
-
-
0031557664
-
Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver
-
Schwer H, Langmann T, Daig R, et al. Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 1997;233:117-20.
-
(1997)
Biochem Biophys Res Commun
, vol.233
, pp. 117-120
-
-
Schwer, H.1
Langmann, T.2
Daig, R.3
-
29
-
-
0032440452
-
Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
-
Guichard S, Morton CL, Krull EJ, et al. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res 1998;4:3089-94.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 3089-3094
-
-
Guichard, S.1
Morton, C.L.2
Krull, E.J.3
-
30
-
-
0031975059
-
Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11
-
Danks MK, Morton CL, Pawlik CA, Potter PM. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998;58:20-2.
-
(1998)
Cancer Res
, vol.58
, pp. 20-22
-
-
Danks, M.K.1
Morton, C.L.2
Pawlik, C.A.3
Potter, P.M.4
-
31
-
-
23944470597
-
Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety
-
Hyatt JL, Stacy V, Wadkins RM, et al. Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. J Med Chem 2005;48:5543-50.
-
(2005)
J Med Chem
, vol.48
, pp. 5543-5550
-
-
Hyatt, J.L.1
Stacy, V.2
Wadkins, R.M.3
-
32
-
-
29744447165
-
Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
-
Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs 2005;23:539-45.
-
(2005)
Invest New Drugs
, vol.23
, pp. 539-545
-
-
Ando, M.1
Hasegawa, Y.2
Ando, Y.3
-
33
-
-
0029741368
-
Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
-
Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-7.
-
(1996)
Cancer Res
, vol.56
, pp. 3752-3757
-
-
Takasuna, K.1
Hagiwara, T.2
Hirohashi, M.3
-
34
-
-
33644841966
-
Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors
-
Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-70.
-
(2006)
J Clin Oncol
, vol.24
, pp. 563-570
-
-
Furman, W.L.1
Crews, K.R.2
Billups, C.3
|